Show simple item record

dc.contributor.authorGudjonsson, H
dc.contributor.authorOddsson, E
dc.contributor.authorBjornsson, S
dc.contributor.authorGunnlaugsson, O
dc.contributor.authorTheodors, A
dc.contributor.authorJonasson, T A
dc.contributor.authorBonnevie, O
dc.contributor.authorThjodleifsson, B
dc.date.accessioned2011-02-17T15:06:13Z
dc.date.available2011-02-17T15:06:13Z
dc.date.issued1993-11
dc.date.submitted2011-02-17
dc.identifier.citationScand. J. Gastroenterol. 1993, 28(11):969-72en
dc.identifier.issn0036-5521
dc.identifier.pmid8284632
dc.identifier.doi10.3109/00365529309098293
dc.identifier.urihttp://hdl.handle.net/2336/122159
dc.descriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links fielden
dc.description.abstractThe object of this study was to assess the efficacy of sucralfate in the treatment of non-ulcer dyspepsia (NUD). The diagnosis of NUD was made by exclusion. All patients underwent an upper gastrointestinal endoscopy and abdominal ultrasound, and blood tests were done as clinically indicated. Patients with a history of peptic ulcer disease were not included. Symptomatic assessment was made at the beginning and at the end of the study. The patients registered their most prominent dyspeptic symptoms and whether they improved, were unchanged, or worsened. The study was double-blind. Placebo or 1 g sucralfate four times daily was given for 3 weeks. Over a 2-year period 104 patients were included in the study; 56 received sucralfate and 48 placebo. Nine patients were excluded because of poor compliance or side effects, six from the sucralfate group and three from the placebo group. The sucralfate and placebo groups were comparable with regard to symptom and clinical variables. Global assessment of symptoms showed that in the sucralfate group 34 improved (68%), 11 were unchanged, and 5 were worse. In the placebo group 31 improved (69%), 11 were unchanged, and 3 were worse. There was no statistically significant difference between the groups. The 3-week course of sucralfate in patients with NUD did not show symptomatic improvement over placebo.
dc.language.isoenen
dc.publisherInforma Healthcareen
dc.relation.urlhttp://dx.doi.org/10.3109/00365529309098293en
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshDouble-Blind Methoden
dc.subject.meshDyspepsiaen
dc.subject.meshFemaleen
dc.subject.meshFollow-Up Studiesen
dc.subject.meshHumansen
dc.subject.meshMaleen
dc.subject.meshMiddle Ageden
dc.subject.meshSex Factorsen
dc.subject.meshSucralfateen
dc.subject.meshTreatment Outcomeen
dc.titleEfficacy of sucralfate in treatment of non-ulcer dyspepsia. A double-blind placebo-controlled studyen
dc.typeArticleen
dc.contributor.departmentDept. of Medicine, National University Hospital, Reykjavík, Iceland.en
dc.identifier.journalScandinavian journal of gastroenterologyen
html.description.abstractThe object of this study was to assess the efficacy of sucralfate in the treatment of non-ulcer dyspepsia (NUD). The diagnosis of NUD was made by exclusion. All patients underwent an upper gastrointestinal endoscopy and abdominal ultrasound, and blood tests were done as clinically indicated. Patients with a history of peptic ulcer disease were not included. Symptomatic assessment was made at the beginning and at the end of the study. The patients registered their most prominent dyspeptic symptoms and whether they improved, were unchanged, or worsened. The study was double-blind. Placebo or 1 g sucralfate four times daily was given for 3 weeks. Over a 2-year period 104 patients were included in the study; 56 received sucralfate and 48 placebo. Nine patients were excluded because of poor compliance or side effects, six from the sucralfate group and three from the placebo group. The sucralfate and placebo groups were comparable with regard to symptom and clinical variables. Global assessment of symptoms showed that in the sucralfate group 34 improved (68%), 11 were unchanged, and 5 were worse. In the placebo group 31 improved (69%), 11 were unchanged, and 3 were worse. There was no statistically significant difference between the groups. The 3-week course of sucralfate in patients with NUD did not show symptomatic improvement over placebo.


This item appears in the following Collection(s)

Show simple item record